# A Trial of Prednisolone in Combination With SPI-62 or Placebo in Subjects With Polymyalgia Rheumatica (PMR)

> **NCT05436652** · PHASE2 · COMPLETED · sponsor: **Sparrow Pharmaceuticals** · enrollment: 66 (actual)

## Conditions studied

- Polymyalgia Rheumatica

## Interventions

- **DRUG:** SPI-62
- **DRUG:** SPI-62 matched placebo
- **DRUG:** Prednisolone 10mg
- **DRUG:** Additional prednisolone
- **DRUG:** Additional prednisolone matched placebo

## Key facts

- **NCT ID:** NCT05436652
- **Lead sponsor:** Sparrow Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-22
- **Primary completion:** 2025-04-25
- **Final completion:** 2025-04-25
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2025-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05436652

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05436652, "A Trial of Prednisolone in Combination With SPI-62 or Placebo in Subjects With Polymyalgia Rheumatica (PMR)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05436652. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*